Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A3 | O75751 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 4/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.68 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metanephrine SCHEMBL29569242 | 1.00 | SLC22A3 (0.73) | SLC22A3TSHRCYP3A4TDP1KDM4E | |
| Metanephrine SCHEMBL30512034 | 1.00 | SLC22A3 (0.73) | SLC22A3TSHRCYP3A4TDP1KDM4E | |
| Metanephrine SCHEMBL2471378 | 0.98 | SLC22A3 (0.71) | SLC22A3TSHRCYP3A4TDP1KDM4E | |
| Metanephrine SCHEMBL2771744 | 0.93 | NFKB1 (0.81) | SLC22A3TSHRCYP3A4TDP1KDM4E | |
| SCHEMBL11647079 | 0.87 | KDM4E (0.68) | SLC22A3TSHRCYP3A4TDP1KDM4E | |
| SCHEMBL29511863 | 0.87 | HIF1A (0.58) | SLC22A3TSHRCYP3A4TDP1KDM4E | |
| SCHEMBL3652526 | 0.87 | HIF1A (0.58) | SLC22A3TSHRCYP3A4TDP1KDM4E | |
| SCHEMBL18740843 | 0.86 | SLC22A3 (0.56) | SLC22A3TSHRCYP3A4TDP1KDM4E | |
| SCHEMBL2691392 | 0.86 | KDM4E (0.66) | SLC22A3TSHRCYP3A4TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL3656870 | 0.85 | ADRB2 (0.59) | SLC22A3TSHRCYP3A4TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4562182-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-06-04 | — | — | EP | claimed |
| WO-2025016307-A1 | HEALTH HOMEOSTASIS MODEL, ELASTIC HOMEOSTASIS MODEL, AND USAGE METHOD THEREFOR | 汤臣倍健股份有限公司 | 2025-01-23 | — | — | WO | claimed |
| CN-118980810-A | Method for early diagnosis of motor muscle micro-injury by using saliva metabolite type biomarker | 北京理工大学 | 2024-11-19 | — | — | CN | claimed |
| US-12117457-B2 | Method for simultaneous analysis of neurotransmitters and their metabolites based on derivatization | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-10-15 | — | — | US | claimed |
| US-20240310368-A1 | DETECTION KIT FOR CATECHOLAMINES AND METABOLITES THEREOF IN PLASMA/URINE AND DETECTION METHOD THEREOF | Calibra Scientific, Inc. (CN) | 2024-09-19 | — | — | US | claimed |
| US-20240047065-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | UNIVERSITY OF DUNDEE (GB) | 2024-02-08 | — | — | US | claimed |
| WO-2024023324-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2024-02-01 | — | — | WO | claimed |
| EP-4292102-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2023-12-20 | — | — | EP | claimed |
| US-20230323168-A1 | CATECHOL MODIFIERS FOR EPOXY ADHESIVES | ZYMERGEN INC. | 2023-10-12 | — | — | US | claimed |
| WO-2004080468-A1 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ALKALINE PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-23 | — | — | WO | claimed |
| US-20040072187-A1 | Novel mammalian receptor genes and uses | OREGON HEALTH & SCIENCE UNIVERSITY | 2004-04-15 | — | — | US | claimed |
| EP-1319070-A2 | MAMMALIAN RECEPTOR GENES AND USES | Oregon Health & Science University (US) | 2003-06-18 | — | — | EP | claimed |
| US-20030078231-A1 | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties | WILBURN MICHAEL D (US) | 2003-04-24 | — | — | US | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| US-20020182600-A1 | Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques | SMITH JACK V (US) | 2002-12-05 | — | — | US | claimed |
| WO-2002022801-A2 | MAMMALIAN RECEPTOR GENES AND USES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2002-03-21 | — | — | WO | claimed |
| US-4591551-A | ENZYMATIC TRANSMETHYLATION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1986-05-27 | — | — | US | claimed |
| US-4287368-A | BY OXIDATION OF METANEPHRINE OR NORMETANEPHRINE WITH A PERIODATE | THE UPJOHN COMPANY (US) | 1981-09-01 | — | — | US | claimed |
| US-4108973-A | OXIDATION | HOFFMANN-LA ROCHE INC. (US) | 1978-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078231-A1 | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties | MAT1A, LPO, TPMT | SLC22A3 3686/4885TSHR 3900/4885CYP3A4 2763/4885 |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | RBP4, RBP1, VDR | SLC22A3 1685/4885TSHR 2780/4885CYP3A4 2879/4885 |
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | SHBG, HSD11B2, HSD11B1 | SLC22A3 1104/4885TSHR 1111/4885CYP3A4 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.